Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

OKYO Pharma (OKYO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow OKYO Pharma Ltd's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.535 -0.195    -7.14%
29/07 - Closed. Currency in USD
After Hours
2.540
+0.005
+0.197%
23:51:43 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 95,480
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.500 - 2.743
OKYO Pharma Ltd 2.535 -0.195 -7.14%

OKYO Pharma Company Profile

 
Get an in-depth profile of OKYO Pharma, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

3

Equity Type

ORD

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Contact Information

Address 14/15 Conduit St Floor 4
London, W1S 2XJ
United Kingdom
Phone 44 20 7495 2379
Fax -

Top Executives

Name Age Since Title
Mark Milner - 2024 Member of Scientific Advisory Board
Anat Galor - 2024 Member of Scientific Advisory Board
John Patrick Brancaccio 76 2020 Independent Non-Executive Director
Gabriele Marco Antonio Cerrone 53 2021 Non-Executive Chairman
Willy Jules Simon 74 2015 Senior Independent Non-Executive Director
Bernard F. Denoyer 78 2021 Independent Non-Executive Director
Gary S. Jacob 78 2021 CEO & Executive Director
Jay S. Pepose 69 2023 Member of Scientific Advisory Board
Napoleone Ferrara 68 2020 Member of Scientific Advisory Board
Pedram Hamrah - - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OKYO Comments

Write your thoughts about OKYO Pharma
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email